It has now been almost 18 months since I started my CEO Perspectives blog. From the questions and comments I get about my posts, I can tell that many people...
Read More Pulmonary Arterial Hypertension is Associated with Elevated Levels of Galectin-3 and a Potential Therapeutic Target for GR-MD-02
1 Comments , in Article
Elevated levels of the Galectin-3 protein are associated with multiple disease processes, in addition to those Galectin Therapeutics is addressing in ongoing clinical trials such as fatty liver disease, psoriasis...
Read More
By Peter G. Traber, M.D. on April 28, 2016 Last September, Galectin Therapeutics began a Phase 2a open-label clinical trial with GR-MD-02, our galectin-3 inhibitor drug, in patients with moderate-to-severe...
Read More
By Peter G. Traber, M.D. on March 17, 2016 We often talk about how Galectin Therapeutics’ proprietary compound, GR-MD-02, is protected by a strong intellectual property portfolio. I thought it...
Read More
By Galectin Therapeutics. on January 7, 2016 The many accomplishments at Galectin Therapeutics during 2015 ranged from incremental progress touching every aspect of our business to significant advancements with GR-MD-02. Importantly,...
Read More Second Phase 2 clinical trial initiated for fatty liver disease with advanced fibrosis
0 Comments , in Article
Written by Peter G. Traber, M.D. on September 16, 2015 As a company, we are focused on developing a therapy for patients with non-alcoholic steatohepatitis (NASH), or fatty liver disease,...
Read More
Written by Peter G. Traber, M.D. on September 9, 2015 An important question in drug development, and the subject of U.S. Food and Drug Administration (FDA) regulations, is whether a...
Read More Successful Phase 1 Clinical Trial Supports Phase 2 Clinical Development Program
1 Comments , in Article
Written by Peter G. Traber, M.D. on August 24, 2015 Galectin Therapeutics completed and reported on a successful Phase 1 clinical trial in NASH patients with advanced fibrosis. In a...
Read More
Written by Peter G. Traber, M.D. on July 31, 2015 During the normal course of conducting business in a public company like Galectin Therapeutics, as the CEO and Chief Medical...
Read More